J Korean Ophthalmol Soc > Volume 60(2); 2019 > Article
Journal of the Korean Ophthalmological Society 2019;60(2):135-143.
DOI: https://doi.org/10.3341/jkos.2019.60.2.135    Published online February 15, 2019.
One-year Outcome of Intravitreal Dexamethasone Implant for Diabetic Macular Edema Patients.
No Hae Park, Hyun Duck Kwak, Chang Ki Yoon, Ji Eun Lee, Min Sagong, Sang Joon Lee, Joo Eun Lee, Kun Hyung Kim, Hyun Woong Kim
1Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
2Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. maekbak@hanmail.net
3Department of Ophthalmology, Pusan National University School of Medicine, Yangsan, Korea.
4Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Korea.
5Department of Ophthalmology, Kosin University College of Medicine, Busan, Korea.
6Jea Seung Youn's Eyeclinic, Busan, Korea.
7Institute of Environmental and Occupational Medicine, Department of Occupational and Environmental Medicine, Inje University College of Medicine, Busan, Korea.
당뇨황반부종에서 유리체강내 덱사메타손삽입물 치료의 1년 효과
인제대학교 의과대학 부산백병원 안과학교실1, 인제대학교 의과대학 해운대백병원 안과학교실2, 부산대학교 의학전문대학원 안과학교실3, 영남대학교 의과대학 안과학교실4, 고신대학교 의과대학 안과학교실5, 제승연안과6, 인제대학교 의과대학 환경산업의학연구소7
Correspondence:  Hyun Woong Kim,
Email: maekbak@hanmail.net
Received: 26 July 2018   • Revised: 2 October 2018   • Accepted: 24 January 2019
The 1-year outcomes of intravitreal dexamethasone implants in diabetic macular edema (DME) patients were evaluated. METHODS: The medical records of 67 patients (70 eyes) with DME were reviewed retrospectively. All patients were treated with intravitreal dexamethasone implants more than twice a year and followed up for at least 1 year from the first dexamethasone implant injection. The best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were measured at every visit after the first injection. Adverse effects, including cataract formation and elevation of IOP, were analyzed. RESULTS: The mean patient age was 58.72 ± 9.91 years and 38 patients were male. The average number of injections was 2.73 ± 0.65 and the interval between injections was 21.52 ± 8.47 weeks. The average baseline BCVA and CMT were 0.59 ± 0.30 logMAR and 457.17 ± 133.10 µm, respectively. The BCVA was significantly improved from 3 months after the first injection, but this result did not last for 1 year. The CMT was significantly decreased compared to baseline for 1 year (p < 0.001). Group analysis revealed that the BCVA improved significantly in the group with HbA1c < 8.1% compared to the group with HbA1c ≥ 8.1% (p = 0.044), and the CMT improved significantly in the group with absent subretinal fluid compared to the group with the presence of subretinal fluid (p = 0.009). An elevated IOP was observed in 18 eyes (24%), and cataract formation was observed in 10 eyes (14%). CONCLUSIONS: Intravitreal dexamethasone implants resulted in visual acuity stabilization and macular edema reduction in patients with DME.
Key Words: Dexamethasone;Diabetes mellitus;Macular edema

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next